Community Research and Development Information Service - CORDIS

A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novelinnovative drug for the treatment of type 2 diabetes

From 2016-11-01 to 2018-06-30, ongoing project

Project details

Total cost:

EUR 2 604 625

EU contribution:

EUR 1 823 237,50

Coordinated in:

Sweden

Call for proposal:

H2020-SMEINST-2-2016-2017See other projects for this call

Funding scheme:

SME-2 - SME instrument phase 2

Objective

Coordinator

BETAGENON AB
Sweden

EU contribution: EUR 1 823 237,50


TVISTEVAGEN 48C
907 36 UMEA
Sweden
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top